Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xanax XR continuation in adolescents with panic disorder
NCT00635076Phase 4Terminated
- Sponsor
- Viatris
- Start
- Jul 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in panic disorder comparing Placebo group with Alprazolam XR group (2 arms). Primary endpoints: Baseline-to-peak Physician Withdrawal Checklist change score during taper off Alprazolam at Week 29, The incidence of treatment-emergent adverse events during 6 months of treatment with alprazolam XR at Week 24 and 1 more. Started Jul 2004; status: terminated.
02
Drugs
alprazolam
03
Conditions
panic disorder
Beyond the preview
Go deeper on NCT00635076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00635076.